Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?

8 The overall survival analysis did not reach statistical significance in the ITT population and showed a clinically meaningful improvement of 7.5 months in overall survival (25.0 vs 18.0 months HR 0.71; 95% CI 0.54 to 0.94) in the PD-L1 positive population, although this hypothesis was formally not allowed to be tested according to the statistical plan of the study.

also in 111,027 other papers